Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?
In the run up to the Hong Kong stock exchange’s anticipated rule change — opening the door for Chinese pre-revenue biotechs to go public closer to home — more than a year ago, Tasly Biopharma was one of the big players whose rumored interest helped stoke enthusiasm for the new listing venue. The company has since kept the drumroll rumbling in the background, raising a pre-IPO round and convincing partner Transgene to swap ownership in a joint venture for equity. Now the other shoe has finally dropped as execs outline plans for a pipeline dominated by cardiovascular drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.